HC Wainwright Issues Negative Estimate for BCYC Earnings

Bicycle Therapeutics plc (NASDAQ:BCYC) – Analysts at HC Wainwright decreased their Q1 2025 earnings estimates for Bicycle Therapeutics in a research note issued on Wednesday, February 26th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.99) for the quarter, down from their prior forecast of ($0.93). HC Wainwright has a “Buy” rating and a $33.00 price objective on the stock. The consensus estimate for Bicycle Therapeutics’ current full-year earnings is ($3.06) per share. HC Wainwright also issued estimates for Bicycle Therapeutics’ Q2 2025 earnings at ($0.99) EPS, FY2025 earnings at ($3.90) EPS, FY2026 earnings at ($4.31) EPS, FY2027 earnings at ($3.45) EPS, FY2028 earnings at ($1.56) EPS and FY2029 earnings at $1.20 EPS.

Other equities analysts have also issued reports about the stock. JMP Securities decreased their target price on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating on the stock in a report on Wednesday, December 18th. Stephens reaffirmed an “equal weight” rating and set a $15.00 price target on shares of Bicycle Therapeutics in a report on Wednesday, January 22nd. Royal Bank of Canada reaffirmed an “outperform” rating and set a $35.00 price target on shares of Bicycle Therapeutics in a report on Friday, November 1st. B. Riley cut their target price on shares of Bicycle Therapeutics from $28.00 to $17.00 and set a “neutral” rating on the stock in a research report on Friday, December 13th. Finally, Needham & Company LLC restated a “buy” rating and issued a $30.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $29.14.

Bicycle Therapeutics Stock Performance

NASDAQ:BCYC opened at $11.03 on Friday. Bicycle Therapeutics has a 52 week low of $10.91 and a 52 week high of $28.67. The firm has a market cap of $761.62 million, a price-to-earnings ratio of -3.35 and a beta of 0.93. The firm’s 50-day simple moving average is $13.35 and its 200 day simple moving average is $19.46.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its earnings results on Tuesday, February 25th. The company reported ($0.75) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.10. The company had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $5.47 million. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. Bicycle Therapeutics’s quarterly revenue was down 30.2% compared to the same quarter last year. During the same quarter last year, the company posted ($1.16) EPS.

Insider Buying and Selling

In other news, CEO Kevin Lee sold 9,038 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total transaction of $127,345.42. Following the completion of the sale, the chief executive officer now owns 495,026 shares of the company’s stock, valued at approximately $6,974,916.34. This represents a 1.79 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Bros. Advisors Lp Baker acquired 985,397 shares of the company’s stock in a transaction dated Friday, December 13th. The shares were bought at an average cost of $13.76 per share, with a total value of $13,559,062.72. Following the purchase, the director now owns 9,537,643 shares of the company’s stock, valued at approximately $131,237,967.68. This trade represents a 11.52 % increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have sold 27,677 shares of company stock valued at $392,413. 8.50% of the stock is owned by insiders.

Institutional Trading of Bicycle Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in BCYC. FMR LLC purchased a new position in Bicycle Therapeutics during the third quarter valued at $3,406,000. The Manufacturers Life Insurance Company lifted its position in Bicycle Therapeutics by 33.2% during the third quarter. The Manufacturers Life Insurance Company now owns 129,705 shares of the company’s stock valued at $2,935,000 after buying an additional 32,313 shares during the period. Principal Financial Group Inc. purchased a new position in Bicycle Therapeutics during the third quarter valued at $10,028,000. State Street Corp lifted its position in Bicycle Therapeutics by 233.5% during the third quarter. State Street Corp now owns 86,271 shares of the company’s stock valued at $1,952,000 after buying an additional 60,399 shares during the period. Finally, Jane Street Group LLC lifted its position in Bicycle Therapeutics by 35.7% during the third quarter. Jane Street Group LLC now owns 20,180 shares of the company’s stock valued at $457,000 after buying an additional 5,310 shares during the period. Hedge funds and other institutional investors own 86.15% of the company’s stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.